Regeneron Pharmaceuticals, Inc. (REGN) Q3 2016 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.6%

Regeneron's strong EPS performance, beating expectations by over 38%, led to a positive stock reaction, with shares rising 1.6%. The company continues to focus on its product pipeline and innovation, which may support future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$3.13	N/A	+38.19%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and future growth. They acknowledged challenges but remain focused on innovation.

Management highlighted strong performance in key product areas.

They emphasized ongoing investment in research and development.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.6%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.6%

Key numbers

Management commentary